Will the Addyi female sexual dysfunction pill ever generate any excitement?

Two years after betting $1 billion on the drug, Valeant Pharmaceuticals (VRX) has agreed to sell Sprout Pharmaceuticals, which initially won regulatory approval for the drug, back to its shareholders. The deal ends a lawsuit filed against the drug maker by former Sprout shareholders  – and Valeant is providing a $25 million loan.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Wrong advocacy group. Remember Hall and Oates “She’s a Maneater”. The NOW is a starchy postmenopsusal post womens libbers group that cares more about abortion rights than orgasms.

  • Hmmm – “and interactions with other medicines.” and if memory serves, that would include the ‘medicinal/ social effects of alcohol. This pill was indeed a solution that did seem to be somewhat … lacking.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy